Surface Oncology News

Coherus BioSciences Completes Acquisition of Surface Oncology

Coherus BioSciences (CHRS) said Friday it has completed the acquisition of Surface Oncology (SURF). Upon closing, Coherus issued 0.1960 of its common shares at $5.2831 apiece for every Surface common

MT NewswiresSep 8, 2023 10:21 ET

Coherus Completes Surface Oncology Acquisition

REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the closing of the previously announced acquisition of Surface Oncology, Inc. (Surface or Surface Oncology), a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment.

GlobeNewswireSep 8, 2023 09:05 ET

Surface Oncology Says Takeover by Coherus BioSciences Gets Backing From ISS, Glass Lewis

Surface Oncology (SURF) said independent proxy advisors Institutional Shareholder Services and Glass Lewis recommended stockholders vote in favor of the buyout by Coherus BioSciences (CHRS). If Surfac

MT NewswiresAug 31, 2023 16:39 ET

Surface Oncology Announces ISS And Glass Lewis Both Recommend Stockholders Vote "FOR" The Proposed Merger With Coherus BioSciences >SURF

Surface Oncology Announces ISS And Glass Lewis Both Recommend Stockholders Vote "FOR" The Proposed Merger With Coherus BioSciences >SURF

Dow JonesAug 31, 2023 16:01 ET

Surface Oncology GAAP EPS of -$0.46

Seeking AlphaAug 2, 2023 12:24 ET

Surface Oncology Q2 EPS $(0.46) Misses $(0.34) Estimate

Surface Oncology (NASDAQ:SURF) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.34) by 35.29 percent. This is unchanged from the same period last year.

BenzingaAug 2, 2023 07:15 ET

Express News | Surface Oncology: If Coherus Merger Isn't Approved by Shareholders, Cash Runway Extends Through 2023 >SURF

Moomoo 24/7Aug 2, 2023 07:05 ET

Express News | Surface Oncology 2Q R&D Expenses $13.8M >SURF

Moomoo 24/7Aug 2, 2023 07:04 ET

Press Release: Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023 CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immun

Dow JonesAug 2, 2023 07:00 ET

Express News | Surface Oncology 2Q Loss/Shr 46c >SURF

Moomoo 24/7Aug 2, 2023 07:00 ET

Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023.

GlobeNewswireAug 2, 2023 07:00 ET

Downgrade Aside, Cathie Wood Buys $1.2M Worth Of SoFi Shares

Ark Invest, through its Ark Fintech Innovation ETF fund, purchased 133,191 shares of SoFi Technologies.

BenzingaJul 28, 2023 02:44 ET

Cathie Wood Sells $7M Tesla Stock Friday Amid Pullback, Bets Big On This Crypto-Linked Stock

Cathie Wood's Ark Invest offloaded more Tesla shares on Friday even as it amassed this crypto-linked stock for a second straight day.

BenzingaJun 24, 2023 02:34 ET

Surface Oncology (SURF) Was Downgraded to a Hold Rating at JonesTrading

TipRanksJun 20, 2023 16:15 ET

Ten Stocks Trending On Discord For Tuesday June 20, 2023: TEVA, BVS, ASB, CLNN, CTG, SURF, DICE, SPY, BABA, TASK

Ten Stocks Trending On Discord For Tuesday June 20, 2023: TEVA, BVS, ASB, CLNN, CTG, SURF, DICE, SPY, BABA, TASK

BenzingaJun 20, 2023 13:25 ET

Wedbush Downgrades Surface Oncology to Neutral From Outperform, Adjusts Price Target to $1.15 From $3

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: Price: 0.81, Change: +0.02,

MT NewswiresJun 20, 2023 11:10 ET

Benzinga's Top Ratings Upgrades, Downgrades For June 20, 2023

UpgradesTudor Pickering upgraded the previous rating for EQT Corp (NYSE:EQT) from Hold to Buy. EQT earned $1.70 in the first quarter, compared to $0.81 in the year-ago quarter. At the moment, the stoc

BenzingaJun 20, 2023 11:02 ET

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Surface Oncology, Inc. Buyout

Wilmington, Delaware--(Newsfile Corp. - June 20, 2023) - Rigrodsky Law, P.A. is investigating Surface Oncology, Inc. ("Surface") (NASDAQ: SURF) regarding possible breaches of fiduciary duties and othe

newsfileJun 20, 2023 10:52 ET

Wedbush Downgrades Surface Oncology to Neutral

Wedbush analyst Robert Driscoll downgrades Surface Oncology (NASDAQ:SURF) from Outperform to Neutral.

BenzingaJun 20, 2023 09:06 ET

Express News | Surface Oncology Cut to Neutral From Outperform by Baird

Moomoo 24/7Jun 20, 2023 07:36 ET